Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 ROC (Joel Greenblatt) % is 38.69% as of Mar. 2025, which is 22% above its 10-year median of 31.71. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Avience Biomedicals ranks better than 83.65% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Avience Biomedicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 38.69%.
The historical rank and industry rank for Avience Biomedicals's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:AVIENCE'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.82 Med: 31.71 Max: 38.69
Current: 38.69
During the past 3 years, Avience Biomedicals's highest ROC (Joel Greenblatt) % was 38.69%. The lowest was 25.82%. And the median was 31.71%.
NSE:AVIENCE's ROC (Joel Greenblatt) % is ranked better than 83.65% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.64
vs NSE:AVIENCE: 38.69
Avience Biomedicals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Avience Biomedicals ROC (Joel Greenblatt) % Related Terms
Avience Biomedicals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals ROC (Joel Greenblatt) % Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
ROC (Joel Greenblatt) %
25.82
31.71
38.69
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
ROC (Joel Greenblatt) %
25.82
31.71
38.69
NSE:AVIENCE vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Avience Biomedicals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is one times the annual (Mar. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 38.69% mean?
Avience Biomedicals (NSE:AVIENCE) has a ROC (Joel Greenblatt) % of 38.69% as of Mar. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avience Biomedicals and its competitors. This is 22% above median its historical median of 31.71. Over the past decade, Avience Biomedicals' ROC (Joel Greenblatt) % has ranged from 25.82 to 38.69. According to the industry distribution chart, Avience Biomedicals ranks #137 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 16.3%.
Is Avience Biomedicals' ROC (Joel Greenblatt) % too high?
Avience Biomedicals' current ROC (Joel Greenblatt) % of 38.69% is 22% above median its 10-year median of 31.71. Over the past 10 years, this metric has ranged from a low of 25.82 to a high of 38.69. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.64. Avience Biomedicals' value of 38.69% is 733.8% above this industry median. Based on the distribution chart, Avience Biomedicals ranks #137 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #137 out of 838 companies for ROC (Joel Greenblatt) %. This places Avience Biomedicals in the top 16% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.64. Avience Biomedicals' value of 38.69% is 733.8% above this benchmark. Historically, Avience Biomedicals' own ROC (Joel Greenblatt) % has ranged from 25.82 to 38.69 over the past decade. While the company's 10-year median is 31.71 vs. the industry median of 4.64, Avience Biomedicals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.64, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current ROC (Joel Greenblatt) % of 38.69% is 733.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current ROC (Joel Greenblatt) % is 38.69%, which is 22% above median its own 10-year median of 31.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current ROC (Joel Greenblatt) % of 38.69%. The current ROC (Joel Greenblatt) % is 38.69%, which is 22% above median its 10-year median of 31.71 and 733.8% above the Medical Devices & Instruments industry median of 4.64. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current ROC (Joel Greenblatt) % is 38.69% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
